Peritoneal Metastases Clinical Trial
Official title:
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
In this phase 2 study, we combined sintilimab, paclitaxel and S-1 as regimen to treat gastric cancer patients with peritoneal metastasis. We are aim to estimate the efficacy and safety of this regimen in the phase 2 study.
Gastric cancer patients enrolled in this a phase 2 study received sintilimab (200mg intravenously on day 1), paclitaxel (PTX) (20 mg/m2 intraperitoneally and 50 mg/m2 intravenously on days 1 and 8) plus oral S-1 (80 mg/m2 for 14 consecutive days) every 3 weeks. The primary endpoint is 1-year survival rate. Secondary endpoints are adverse events, R0 resection rate, 3-year overall survival (OS), and 3-year progressive free survival. Adverse events are monitored and graded according to the Common Terminology Criteria for Adverse Events version 4.0. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03422432 -
Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases
|
N/A | |
| Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
| Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 | |
| Recruiting |
NCT05623787 -
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
|
N/A | |
| Not yet recruiting |
NCT05095467 -
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
|
Phase 2 | |
| Completed |
NCT04083547 -
Circulating Tumour Cells in Patients With Peritoneal Metastases
|
||
| Recruiting |
NCT05277766 -
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05318794 -
Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT05665257 -
Feasibility of Preoperative Inspiratory Muscle Training for Patients With Peritoneal Metastases
|
N/A | |
| Recruiting |
NCT05581719 -
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05379790 -
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
|
Phase 1 | |
| Recruiting |
NCT04956068 -
PIPAC for Peritoneal Metastases
|
Phase 1 | |
| Recruiting |
NCT04861558 -
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT05340569 -
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
|
N/A | |
| Recruiting |
NCT03834272 -
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04744688 -
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
|
||
| Completed |
NCT03733184 -
Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases
|
||
| Recruiting |
NCT06046963 -
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
|
Phase 2 | |
| Recruiting |
NCT05755672 -
On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
|
||
| Recruiting |
NCT03757858 -
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
|
Phase 1/Phase 2 |